Current Status of Platinum-Based Antitumor Drugs

This publication has 143 references indexed in Scilit:

• A long-lived ascorbate radical in the platinum(II) catalysed reductions of platinum(IV) antitumor drugs
  J. Chem. Soc., Dalton Trans., 1997
• Cycloplatam: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin
  European Journal Of Cancer, 1995
• New Cisplatin Analogues in Development
  Drugs, 1993
• Comparative cytotoxicity of CI‐973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines
  International Journal of Cancer, 1991
• The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation
  Mutation Research/DNA Repair, 1991
• Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
  New England Journal of Medicine, 1990
• Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting
  New England Journal of Medicine, 1990
• Effect of Glutathione on DNA Repair in Cisplatin-Resistant Human Ovarian Cancer Cell Lines
  JNCI Journal of the National Cancer Institute, 1989
• Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II)
  Chemico-Biological Interactions, 1988
• Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion
  Chemico-Biological Interactions, 1988